Ashvattha Therapeutics Rallies $69M Series B

Apr 27, 2022•about 3 years ago

Amount Raised

$69 Million

Round Type

series b

Description

Ashvattha Therapeutics, a developer of novel hydroxyl dendrimer therapeutics, has secured $69 million in Series B financing.

Company Information

Company

Ashvattha Therapeutics

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech